A Phase I, Multi-Center, Open-Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR104 Given With Prophylactic G-CSF in Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 31 May 2011
At a glance
- Drugs Filgrastim; PR 104
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 31 May 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 01 Mar 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Mar 2011 Planned end date changed from 1 Aug 2008 to 1 Sep 2008 as reported by ClinicalTrials.gov.